Original

Transcriptional regulation of the human bone sialoprotein gene by fibroblast growth factor 2

Liming Zhou^{1,2)} and Yorimasa Ogata^{1,3)}

¹⁾Department of Periodontology, Nihon University School of Dentistry at Matsudo, Matsudo, Japan

²⁾Stomatological Hospital of Anhui Medical University, Anhui, China

³⁾Research Institute of Oral Science, Nihon University School of Dentistry at Matsudo, Matsudo, Japan

(Received November 27, 2012; Accepted January 11, 2013)

Abstract: Fibroblast growth factor 2 (FGF2), a member of the FGF family, positively regulates bone formation and osteoblast differentiation. Bone sialoprotein (BSP) is highly expressed during early bone formation and may play a role in primary mineralization of bone. In the present study, FGF2 (10 ng/mL) was found to increase the levels of Runx2 and BSP mRNA at 3 and 12 h in human osteoblast-like Saos2 cells. Transient transfection assays were performed using chimeric constructs of the human BSP gene promoter ligated with a luciferase reporter gene. FGF2 (10 ng/mL, 12 h) induced the luciferase activities of the -84LUC and -927LUC constructs in Saos2 cells. The results of gel shift assays showed that FGF2 (10 ng/mL) increased the binding of nuclear protein to the FGF2 response element (FRE) and the activator protein 1 (AP1) binding site. Antibodies against Dlx5, Msx2, Runx2 and Smad1 blocked FRE-protein complex formation, and antibodies against CREB1, c-Jun and Fra2 interrupted AP1-protein complex formation. These results indicate that FGF2 increases BSP transcription by targeting the FRE and AP1 elements in the proximal promoter of the human BSP gene. Moreover, the transcription factors Dlx5, Msx2, Runx2, Smad1, CREB1, c-Jun and Fra2 could be key regulators of the effects of FGF2 on human BSP transcription. (J Oral Sci 55, 63-70, 2013)

Keywords: bone sialoprotein; fibroblast growth factor 2; activator protein 1; gene expression.

Introduction

Fibroblast growth factor 2 (FGF2) is expressed by mesenchymal cells and stored in the extracellular matrix (1,2). In cell culture systems, FGF2 has been shown to decrease osteoblast proliferation, and reduce the levels of mRNA for type I collagen, osteocalcin and alkaline phosphatase (3-5). However, intermittent FGF2 treatment increases bone formation *in vitro* (6). Deletion of the FGF2 gene (*Fgf2*^{-/-} adult mice) results in a decrease of bone mass and bone formation (7), whereas exogenously applied FGF2 induces recovery of bone nodule formation in *Fgf2*^{-/-} bone marrow stromal cell cultures *in vitro* (8). Overexpression of FGF2 (FGF2 transgenic mice) causes a variety of skeletal malformations, including shortening and flattening of long bones and moderate macrocephaly (9). Previously, we have reported that FGF2 activated the tyrosine kinase and mitogen-activated protein kinase (MEK) pathways and induced expression of the bone sialoprotein (BSP) gene in rat osteoblast-like ROS 17/2.8 cells (10). FGF2 increased BSP transcription via FGF2 response element (FRE) in the proximal promoter of the rat BSP gene, which regulates both basal and FGF2-induced BSP transcription (10). We have also reported that the activator protein 1 (AP1) element is another target of FGF2 in the context of BSP transcription (11), and that in addition prostaglandin E₂ induces BSP gene expression through a cAMP response element (CRE) and FRE in the proximal promoter of the rat BSP gene (12).

BSP is a phosphorylated and sulfated non-collagenous glycoprotein found in bone and other mineralizing connective tissues (13-16). Analysis of tissues obtained from 13-, 17- and 21-day fetuses, and from 4-, 14- and

Correspondence to Dr. Yorimasa Ogata, Department of Periodontology, Nihon University School of Dentistry at Matsudo, 2-870-1 Sakaecho-nishi, Matsudo, Chiba 271-8587, Japan
Fax: +81-47-360-9362 E-mail: ogata.yorimasa@nihon-u.ac.jp

100-day-old animals has indicated that expression of BSP mRNA is restricted to cells actively forming the mineralizing tissues of bone, dentin and cementum (17). BSP gene expression has been observed in breast, lung, thyroid and prostate cancers (18-20). These findings suggest that BSP might be involved in the ectopic calcification of metastatic cancers through its ability to bind to calcium and cells through polyglutamic acid and RGD sequences (15,16,21). Therefore, BSP appears to have an important role in the differentiation of osteoblasts, bone formation and tumor metastasis. Studies focusing on BSP gene transcription have cloned and characterized the promoters of the rat, mouse and human BSP genes (22-26). These promoters include an inverted TATA box (-24 to -19) (27) and an inverted CCAAT box (-50 to -46) (28,29). Furthermore, a CRE (-75 to -68) (12,30), a FRE (-92 to -85) (10,12,31,32), a pituitary specific transcription factor-1 (Pit-1) motif (-111 to -105) (33,34), a homeodomain protein binding site (HOX; -199 to -192) (35,36), a transforming growth factor beta (TGF- β) activation element (-499 to -485) (35,37) and a glucocorticoid response element (GRE; -920 to -906) overlapping with AP1 (-921 to -915) have been characterized (14,38).

To determine the molecular mechanism of FGF2 regulation of the human BSP gene, we used Saos2 human osteoblast-like cells to analyze the effects of FGF2 on BSP transcription. We found that FGF2 induces human BSP gene transcription via the FRE and AP1 elements in the human BSP gene promoter.

Materials and Methods

Materials

Alpha minimum essential medium (α -MEM), fetal calf serum (FCS), lipofectamine, penicillin, streptomycin and TrypLE Express were obtained from Invitrogen (Carlsbad, CA, USA). PGL3-basic vector and pSV- β -galactosidase (β -Gal) control vector were purchased from Promega Co. (Madison, WI, USA). An EXScript RT reagent kit and SYBR Premix Ex Taq were purchased from Takara (Tokyo, Japan). All chemicals used were of analytical grade.

Cell culture

The human osteosarcoma cell line, Saos2 (generously provided by Dr. Jaro Sodek, University of Toronto, Canada), was cultured in 10% FCS containing α -MEM. The cells were grown to confluence in 60-mm culture dishes and then cultured in α -MEM without serum and incubated with or without FGF2 (10 ng/mL) for 3, 6, 12 and 24 h. Nuclear proteins were extracted by addition of extra proteinase inhibitors (the extraction buffer

contained 0.42 M NaCl, 0.2 mM EDTA, 1.5 mM MgCl₂, 1 mM dithiothreitol, 25% glycerol, 0.5 mM phenylmethylsulfonyl fluoride, 2 μ g/mL leupeptin, 2 μ g/mL pepstatin, 1 μ g/mL aprotinin, pH 7.9).

Real-time PCR

One microgram of total RNA was used as a template for synthesis of cDNA using an EXScript RT Reagent Kit. Quantitative real-time PCR was performed using the following primer sets (purchased from Takara, Tokyo, Japan): BSP forward, 5'-CTG-GCACAGGGTATACAGGGTTAG-3'; BSP reverse, 5'-ACTGGTGCCGTTTATGCCTTG-3'; Runx2 forward, 5'-ATGTGTGTTTGTTCAGCAGCA-3'; Runx2 reverse, 5'-TCCCTAAAGTCACTCGGTATGTGTA-3'; GAPDH forward, 5'-GCACCGTCAAGGCTGAGAAC-3'; GAPDH reverse, 5'-ATGGTGGTGAAGACGCCAGT-3' using the SYBR Premix Ex Taq in a TP800 thermal cycler dice real-time system (Takara, Tokyo, Japan). The amplification reactions were performed in a final volume of 25 μ L containing 2 $\times$ SYBR Premix EX Taq (12.5 μ L), 0.2 μ M forward and reverse primers (0.5 μ L) and 50 ng cDNA (5 μ L). To reduce variability between replicates, PCR premixes that contained all reagents except for cDNA were prepared and aliquoted into 0.2-mL tubes. The thermal cycling conditions were 1 cycle at 95°C for 10 s, and 40 cycles at 95°C for 5 s and at 60°C for 30 s. Post-PCR melting curves confirmed the specificity of single-target amplification; fold expression of human BSP relative to GAPDH was determined in quadruplicate, and that of Runx2 relative to GAPDH was determined in triplicate.

Transient transfection assays

Exponentially growing Saos2 cells were used for transient transfection assays. Twenty-four hours after plating, cells at 40-60% confluence were transfected using Lipofectamine reagent. The transfection mixture included 1 μ g of a luciferase (LUC) construct (10) and 2 μ g β -gal plasmid as an internal control. Two days after transfection, Saos2 cells were transferred to medium lacking serum for 12 h, FGF2 was then added, and the cells were cultured for a further 12 h prior to harvesting. The luciferase assays were performed in accordance with the supplier's protocol (picaGene, Toyo Inki, Tokyo, Japan) using a BLR201 luminescence reader (Hitachi Aloka Medical, Ltd, Mitaka, Japan) to measure the luciferase activities.

Gel mobility shift assays

Confluent Saos2 cells in T-75 flasks were transferred to

Fig. 1 Regulation of BSP and Runx2 mRNA levels by FGF2. Relative expressions of the BSP and Runx2 genes after real-time PCR of Saos2 cells treated with FGF2 (10 ng/mL) for 3, 6, 12, and 24 h. The expression of GAPDH was also examined as a control. The amounts of mRNA for BSP and Runx2 relative to that of GAPDH were calculated. The expression of human BSP relative to that of GAPDH was determined in quadruplicate, and that of Runx2 relative to GAPDH was determined in triplicate for each data point; standard errors are shown as vertical lines. Significant differences relative to controls are shown at a probability level of $*P < 0.01$.

α -MEM lacking serum for 12 h and then incubated for 3, 6 and 12 h with FGF2 (10 ng/mL) to prepare the nuclear extracts. Double-stranded oligonucleotides encompassing the inverted CCAAT (-64 to -41, 5'-CGTGACAGT-GATTGGCTGTTGGAA-3'), FRE (-102 to -83, 5'-TTTTCTGGTGAGAATCCACG-3') and AP1(1) (-158 to -129, 5'-CGTTTCTTGTTTATTCAACT-GAGCCTGTGT-3') in the human BSP promoter were prepared. For gel shift assays, the double-stranded oligonucleotides were end-labeled with [γ - 32 P]ATP using T4 polynucleotide kinase. Nuclear proteins (3 μ g) were incubated for 20 min at room temperature with 0.1 pM radiolabeled double-stranded oligonucleotide. After incubation, the protein-DNA complexes were resolved by electrophoresis in 5% non-denaturing acrylamide gels (38/2 acrylamide/bis acrylamide) at 200 V. After electrophoresis, the gels were dried and placed in contact with an imaging plate for autoradiography and analyzed using an image analyzer. Supershift gel shift analyses were performed using antibodies against c-Jun (sc-44), c-Fos (sc-253), JunD (sc-74), Fra-2 (sc-604), Msx2 (sc-15396), Smad1 (sc-7965) (Santa Cruz Biotechnology, Inc.), CRE-binding protein 1 (CREB1; P43, Rockland), Dlx5 (AB5728, Chemicon), and Runx2 (AML3, Calbiochem). Each antibody was added to the reaction mixture and incubated for 3 h at 4°C before electrophoresis under the same conditions as those described above.

Fig. 2 FGF2 upregulates BSP promoter activity in Saos2 cells. Transient transfection of Saos2 cells treated with FGF2 (10 ng/mL) for 12 h was performed to determine the transcriptional activity of chimeric constructs that included various regions of the BSP promoter ligated to a luciferase reporter gene. The transcriptional activity determined from four separate transfections with the constructs pGL3 Basic, -43LUC (-43~+60)~ and -927LUC (-927~+60) were combined, and the values expressed with standard errors. Significant differences relative to controls are shown at probability levels of $*P < 0.1$, $**P < 0.02$, and $***P < 0.05$.

Statistical analysis

Quadruplicate or triplicate samples were analyzed for each experiment, and experiments were replicated to ensure consistency of the responses to the drugs. The significance of differences between controls and treatments was determined using one-way analysis of variance (ANOVA).

Results

Effects of FGF2 on expression of BSP and Runx2 mRNAs in Saos2 cells

Previously we have reported that FGF2 increased the level of BSP mRNA in rat osteoblast-like ROS 17/2.8 cells (10). To study the regulation of human BSP transcription by FGF2, we performed real-time PCR using total RNA extracted from human osteoblast-like Saos2 cells. FGF2 (10 ng/mL) was used to determine the time courses of Runx2 and BSP mRNA expression. Treatment of Saos2 cells with 10 ng/mL FGF2 significantly increased the expression of Runx2 mRNA at 3 h, and the level of BSP mRNA became maximal at 12 h (Fig. 1).

Transient transfection analysis of Rat BSP promoter constructs

To further characterize the effects of FGF2 on activation of the human BSP gene, various sized stretches of the

Fig. 3 Nucleotide sequences of the human BSP gene promoter encompassing an inverted CCAAT box, CRE1, FRE, NF κ B, AP1(1) and HOX are shown from -208 to -43. Upper panel: The positions of the inverted TATA and CCAAT boxes, CRE1, FRE, HOX, CRE2 and the three AP1 sites are shown in the proximal promoter region of the human BSP gene. The numbering of nucleotides is shown relative to the transcription start site (+1). The nucleotide sequences of two cAMP response elements (CRE1 and CRE2) in the human BSP gene promoter are shown from -79 to -72 (TGACATCA) and from -674 to -667 (TGACCTCA).

human BSP gene promoter ligated to a luciferase reporter gene (-43LUC to -927LUC) were transiently transfected into Saos2 cells, and the subsequent transcriptional activities were determined in the presence or absence of FGF2. The results of luciferase analyses indicated that FGF2 at 10 ng/mL increased the transcription of human BSP at 12 h after transfection for constructs between -84LUC and -927LUC (Fig. 2). Included within the DNA sequence unique to the human BSP promoter region is an inverted CCAAT box (ATTGG; nts -54 to -50), together with cAMP response element 1 (CRE1; nts -79 to -72), FRE (nts -96 to -89), AP1(1) (nts -148 to -142), HOX (nts -200 to -191) and CRE2 (nts -674 to -667) (Fig. 3).

Gel mobility shift assays

To identify transcription factors that bind to the inverted CCAAT, FRE and AP1 and mediate the effects of FGF2 on gene expression, double-stranded oligonucleotides were end-labeled and incubated with nuclear proteins (3 μ g) from confluent Saos2 cells that had been cultured with FGF2 (10 ng/mL). With nuclear proteins from control cultures of Saos2 cells, shifts of FRE and AP1 DNA-protein complexes were evident (Fig. 4, lanes 5 and 9). After stimulation with FGF2 (10 ng/mL) for 3, 6 and 12 h, FRE- and AP1-protein complexes were increased at 3 h and maintained almost the same levels of intensity at 6 and 12 h (Fig. 4, lanes 6-8, lanes 10-12).

Fig. 4 FGF2 upregulates nuclear proteins that recognize FRE and AP1(1). Radiolabeled double-stranded CCAAT (-64 CGTGACAGTGATTGGCTGTTGGAA -41), FRE (-102 TTTTCTGGTGAGAAATCCACG -83) and AP1(1) (-158 CGTTTCTTGTATTCAACTGAGCCTGTGT -129) oligonucleotides were incubated with nuclear protein extracts (3 μ g) obtained from Saos2 cells stimulated without (lanes 1, 5, and 9) or with FGF2 (10 ng/mL) for 3 h (lanes 2, 6, and 10), 6 h (lanes 3, 7, and 11), and 12 h (lanes 4, 8, and 12). DNA-protein complexes were separated on 5% polyacrylamide gel in low-ionic-strength Tris-borate buffer, dried under vacuum, and exposed to an imaging plate for quantitation using an image analyzer.

When the inverted CCAAT was used as a probe, a strong band for NF-Y binding, identified from previous reports (28,29), was observed. However, the intensities of these bands did not change after exposure to FGF2 (Fig. 4, lanes 1-4). Competition experiments in which a 40-fold molar excess of FRE and AP1 double-stranded oligonucleotides reduced the amount of complex formation (Fig. 5, lanes 3 and 9) demonstrated that these DNA-protein complexes represented specific interactions. In contrast, mutated FRE (mFRE), HOX and mutated HOX (mHOX) did not compete with FRE DNA-protein complex formation (Fig. 5, lanes 4-6), and mutated AP1 (mAP1), CRE1 and CRE2 did not reduce DNA binding to the AP1 (Fig. 5, lanes 10-12). To further analyze the proteins in the complexes formed with FRE and AP1, we performed supershift gel shift assays using antibodies against several transcription factors. Addition of antibodies against Dlx5, Msx2, Runx2 and Smad1 disrupted FRE-protein complex formation (Fig. 6, lanes 3-6), and antibodies against CREB1, c-Jun and Fra2 partially disrupted AP1-protein complex formation (Fig. 6, lanes 9, 10, and 13).

Fig. 5 Specific binding of nuclear proteins to FRE and AP1(1). Radiolabeled double-stranded FRE and AP1(1) were incubated for 20 min at 21°C with nuclear protein extracts (3 μ g) obtained from Saos2 cells. Competition reactions were performed using a 40-fold molar excess of unlabeled FRE (TTTCTGGT-GAGAATCCACG; lane 3), mutation FRE (mFRE; TTTCTGGcaAGAATCCACG; lane 4), HOX (CTAAACCTTCAATTAAATTCCACAATGC; lane 5), mutation HOX (mHOX; CTAAACCTTCCcT-TAAATTCCACAATGC; lane 6), AP1(1) (CGTT TCTTGTTTATTCAACTGAGCCTGTGT; lane 9), mutation AP1(1) (mAP1(1) CGTTTCTTGT-TATgaAACTGAGCCTGTGT; lane 10), CRE1 (CCACGTTCTGACATCACCTTGGTTCG; lane 11) and CRE2 (ATCAGCTGACCTCACATGCACGA; lane 12). DNA-protein complexes were separated on 5% polyacrylamide gel in low-ionic-strength Tris-borate buffer, dried under vacuum, and exposed to an imaging plate for quantitation using an imaging analyzer.

Discussion

Our studies have shown that FGF2 increased the expression of the BSP gene in human osteoblast-like Saos2 cells by targeting FRE and AP1 elements in the gene promoter. Runx2 is a crucial transcription factor for osteoblast differentiation. Runx2-deficient mice die just after birth without breathing, and display an absence of bone due to arrested osteoblast differentiation (39). In the present study, FGF2 induced the expression of Runx2 and BSP mRNA at 3 h, and the level of BSP mRNA became maximal at 12 h in Saos2 cells (Fig. 1). These results suggest that Runx2 might regulate BSP gene expression.

From luciferase assays, we initially located the FGF2 response region between -184 and -60 in the human BSP gene promoter (Fig. 2), a stretch that encompasses the CRE1, FRE and AP1(1) motifs (Fig. 3). The specific

Fig. 6 Specific binding of nuclear proteins to FRE and AP1(1). Radiolabeled double-stranded FRE and AP1(1) were incubated with nuclear protein extracts (3 μ g) obtained from Saos2 cells stimulated without or with FGF2 (10 ng/mL) for 3 h. Supershift experiments were performed using 0.4 μ g antibodies added separately to each gel shift reaction.

response elements in -184LUC, -116LUC and -84LUC are AP1(1), FRE and CRE1. Involvement of the FRE and AP1(1) elements was confirmed by gel shift assays in which nuclear proteins forming complexes with FRE and AP1(1) were increased by FGF2 (10 ng/mL) in Saos2 cells (Fig. 4). The results of supershift gel assays using antibodies (Fig. 6) indicated that FGF2 induced expression of the human BSP gene through targeting of FRE by Dlx5, Msx2, Runx2 and Smad1, and through targeting of AP1(1) by CREB1, c-Jun and Fra2 in the human BSP gene promoter. There was no additional increase in the activity of -184LUC, which contains an AP1(1) element, in comparison with that of -116LUC (Fig. 2), suggesting that FGF2-induced transcription of BSP through AP1(1) might be weaker than that through FRE. A 40-fold molar excesses of double-stranded CRE1 and CRE2 oligonucleotides was unable to compete for AP1(1)-protein complex formation (Fig. 5, lanes 11 and 12), suggesting that the components of AP1(1), and CRE1 and CRE2 binding proteins are different.

FGF2 is a powerful regulator of cartilage and bone growth and osteoblast differentiation. The levels of FGF2 protein and mRNA are increased by parathyroid hormone (40), prostaglandins (41) and TGF- β (42) in osteoblast-like cells. Moreover, FGF receptors (FGFRs) play an important role in a wide variety of biological activities that require bone growth and differentiation. FGF2 and forskolin (FSK) synergistically increase osteo-

calcin transcription via an osteocalcin FRE (OCFRE; GCAGTCA), which is juxtaposed to Runx2 (Osf2, Cbfa1) (43,44). In a previous study, we identified a FRE (-92 to -85, GGTGAGAA) in the rat BSP gene promoter that is juxtaposed with a putative Runx2 site (10). This BSP FRE is a rare element, because FGF2 alone was able to increase the expression of the BSP gene. We have previously reported that the AP1 element overlapping with GRE in the rat BSP gene promoter is another target of FGF2 (11,14). AP1 mediates signaling of the FGF, but not activin, receptor during mesoderm induction, and AP1/Jun is a key signaling molecule in the development of posterior structure (45). FGF2 increases the transcription of matrix metalloproteinase 1 in NIH3T3 fibroblasts via AP1 (46), and induces binding of nuclear proteins from osteoblast-like ROS17/2.8 cells to consensus AP1 (10). These findings indicate that AP1 may be a crucial response element for FGF2-induced transcription.

BMP2 has been reported to induce Dlx2 and Dlx5 gene expression within 30 min in mouse osteoblast-like cells (47). BMP2-induced expression of Runx2 is mediated by Dlx5, and TGF- β opposes the BMP2-induced differentiation of osteoblasts induced by suppression of Dlx5 (48). Dlx5 regulates the transcription of osteocalcin by antagonizing the repression of Msx2 (49). TGF- β signaling from the cell membrane to the nucleus is mediated via Smad transcription factors (50). Smads interact with the MMP1 AP1 site and mediate the repression of MMP-1 gene expression induced by TGF- β 1 (51). FRE (GGTGAGAA) and AP1(1) (TTATTCA) in the human BSP gene promoter (Fig. 3) are very similar to the consensus AP1 (TGAGTCA) and consensus CRE (TGACGTC) sequences, suggesting that the proteins binding to FRE are Dlx5, Msx2, Runx2 and Smad1, and that those binding to AP1(1) are CREB1, c-Jun and Fra2. CRE-binding proteins have a basic region adjacent to a leucine zipper motif (52) that is responsible for their dimerization and DNA binding (53). CREB, CRE modulator (CREM) and ATFs can bind to CRE as homodimers or heterodimers (54), and in the present study we found that CREB and AP1 family transcription factors (c-Jun and Fra2) interacted with AP1(1) in the promoter of the human BSP gene (Fig. 6).

In conclusion, we have characterized the human BSP gene promoter that is required for FGF2-regulated transcription. This promoter region contains FRE and AP1(1), which are required for the FGF2 response. Furthermore, the transcription factors Dlx5, Msx2, Runx2, Smad1, CREB1, c-Jun and Fra2 appear to be key regulators of the effects of FGF2 on BSP gene expression.

Acknowledgments

This work was supported in part by a Grant-in-Aid for Scientific Research (C; No. 22592319), a grant from the Supporting Project for Strategic Research in Private Universities by the Ministry of Education, Culture, Sports, Science, and Technology, Japan (MEXT), 2008-2012, and a grant from the Strategic Research Base Development Program for Private Universities of MEXT, 2010-2014 (S1001024).

References

1. Hauschka PV, Mavrakos AE, Iafrafi MD, Doleman SE, Klagsbrun M (1986) Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. *J Biol Chem* 261, 12665-12674.
2. Globus RK, Plouet J, Gospodarowicz D (1989) Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix. *Endocrinology* 124, 1539-1547.
3. Canalis E, Centrella M, McCarthy T (1988) Effects of basic fibroblast growth factor on bone formation in vitro. *J Clin Invest* 81, 1572-1577.
4. Rodan SB, Wesolowski G, Yoon K, Rodan GA (1989) Opposing effects of fibroblast growth factor and pertussis toxin on alkaline phosphatase, osteopontin, osteocalcin, and type I collagen mRNA levels in ROS 17/2.8 cells. *J Biol Chem* 264, 19934-19941.
5. Hurley MM, Abreu C, Harrison JR, Lichtler AC, Raisz LG, Kream BE (1993) Basic fibroblast growth factor inhibits type I collagen gene expression in osteoblastic MC3T3-E1 cells. *J Biol Chem* 268, 5588-5593.
6. Hurley MM, Marie PJ, Florkiewicz RZ (2002) Fibroblast growth factor (FGF) and FGF receptor families. In: *Principles of bone biology*, 2nd ed, Bilezikian JP, Raisz JG, Rodan GA eds, Academic Press, San Diego, 825-852.
7. Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T et al. (2000) Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. *J Clin Invest* 105, 1085-1093.
8. Naganawa T, Xiao L, Abogunde E, Sobue T, Kalajzic I, Sabbieti M et al. (2006) In vivo and in vitro comparison of the effects of FGF-2 null and haplo-insufficiency on bone formation in mice. *Biochem Biophys Res Commun* 339, 490-498.
9. Coffin JD, Florkiewicz RZ, Neumann J, Mort-Hopkins T, Dorn GW II, Lightfoot P et al. (1995) Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. *Mol Biol Cell* 6, 1861-1873.
10. Shimizu-Sasaki E, Yamazaki M, Furuyama S, Sugiya H, Sodek J, Ogata Y (2001) Identification of a novel response element in the rat bone sialoprotein (BSP) gene promoter that mediates constitutive and fibroblast growth factor 2-induced expression of BSP. *J Biol Chem* 276, 5459-5466.
11. Takai H, Araki S, Mezawa M, Kim DS, Li X, Yang L et al. (2008) AP1 binding site is another target of FGF2 regulation of bone sialoprotein gene transcription. *Gene* 410, 97-104.

12. Samoto H, Shimizu E, Matsuda-Honjo Y, Saito R, Nakao S, Yamazaki M et al. (2003) Prostaglandin E2 stimulates bone sialoprotein (BSP) expression through cAMP and fibroblast growth factor 2 response elements in the proximal promoter of the rat BSP gene. *J Biol Chem* 278, 28659-28667.
13. Oldberg Å, Franzén A, Heinegård D (1988) The primary structure of a cell-binding bone sialoprotein. *J Biol Chem* 263, 19430-19432.
14. Ogata Y, Yamauchi M, Kim RH, Li JJ, Freedman LP, Sodek J (1995) Glucocorticoid regulation of bone sialoprotein (BSP) gene expression. Identification of a glucocorticoid response element in the bone sialoprotein gene promoter. *Eur J Biochem* 230, 183-192.
15. Ganss B, Kim RH, Sodek J (1999) Bone sialoprotein. *Crit Rev Oral Biol Med* 10, 79-98.
16. Ogata Y (2008) Bone sialoprotein and its transcriptional regulatory mechanism. *J Periodontal Res* 43, 127-135.
17. Chen J, Shapiro HS, Sodek J (1992) Developmental expression of bone sialoprotein mRNA in rat mineralized connective tissues. *J Bone Miner Res* 7, 987-997.
18. Bellahcène A, Merville MP, Castronovo V (1994) Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. *Cancer Res* 54, 2823-2826.
19. Waltregny D, Bellahcène A, de Leval X, Florkin B, Weidle U, Castronovo V (2000) Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. *J Bone Miner Res* 15, 834-843.
20. Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC et al. (2000) Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. *Clin Exp Metastasis* 18, 253-260.
21. Hunter GK, Goldberg HA (1993) Nucleation of hydroxyapatite by bone sialoprotein. *Proc Natl Acad Sci USA* 90, 8562-8565.
22. Kerr JM, Fisher LW, Termine JD, Wang MG, McBride OW, Young MF (1993) The human bone sialoprotein gene (IBSP): genomic localization and characterization. *Genomics* 17, 408-415.
23. Li JJ, Sodek J (1993) Cloning and characterization of the rat bone sialoprotein gene promoter. *Biochem J* 289, 625-629.
24. Kim RH, Shapiro HS, Li JJ, Wrana JL, Sodek J (1994) Characterization of the human bone sialoprotein (BSP) gene and its promoter sequence. *Matrix Biol* 14, 31-40.
25. Benson MD, Aubin JE, Xiao G, Thomas PE, Franceschi RT (1999) Cloning of a 2.5 kb murine bone sialoprotein promoter fragment and functional analysis of putative *Osf2* binding sites. *J Bone Miner Res* 14, 396-405.
26. Kiyoshima T, Yamauchi M, Wong C, Jheon A, Ganss B, Sodek J (2002) An L1 element disrupts human bone sialoprotein promoter: lack of tissue-specific regulation by distalless5 (*Dlx5*) and runt homeodomain protein2 (*Runx2*)/core binding factor a1 (*Cbfa1*) elements. *Gene* 299, 205-217.
27. Li JJ, Kim RH, Sodek J (1995) An inverted TATA box directs downstream transcription of the bone sialoprotein gene. *Biochem J* 310, 33-40.
28. Kim RH, Sodek J (1995) Transcription of the bone sialoprotein gene is stimulated by v-Src acting through an inverted CCAAT box. *Cancer Res* 59, 565-571.
29. Shimizu E, Ogata Y (2002) Activation of bone sialoprotein gene transcription by flavonoids is mediated through an inverted CCAAT box in ROS 17/2.8 cells. *J Cell Biochem* 86, 35-44.
30. Li X, Kato N, Mezawa M, Li Z, Wang Z, Yang L et al. (2010) Transcriptional regulation of bone sialoprotein gene by *Porphyromonas gingivalis* lipopolysaccharide. *J Cell Biochem* 110, 823-833.
31. Wang S, Sasaki Y, Zhou L, Matsumura H, Araki S, Mezawa M et al. (2011) Transcriptional regulation of bone sialoprotein gene by interleukin-11. *Gene* 476, 46-55.
32. Li X, Zhou L, Takai H, Sasaki Y, Mezawa M, Li Z et al. (2012) *Aggregatibacter actinomycetemcomitans* lipopolysaccharide regulates bone sialoprotein gene transcription. *J Cell Biochem* 113, 2822-2834.
33. Ogata Y, Nakao S, Kim RH, Li JJ, Furuyama S, Sugiya H et al. (2000) Parathyroid hormone regulation of bone sialoprotein (BSP) gene transcription is mediated through a pituitary specific transcription factor-1 (*Pit-1*) motif in the rat BSP gene promoter. *Matrix Biol* 19, 395-407.
34. Shimizu E, Nakayama Y, Nakajima Y, Kato N, Takai H, Kim DS et al. (2006) Fibroblast growth factor 2 and cyclic AMP synergistically regulate bone sialoprotein gene expression. *Bone* 39, 42-52.
35. Shimizu E, Nakajima Y, Kato N, Nakayama Y, Saito R, Samoto H et al. (2004) Regulation of rat bone sialoprotein gene transcription by enamel matrix derivative. *J Periodontol* 75, 260-267.
36. Nakayama Y, Nakajima Y, Kato N, Takai H, Kim DS, Arai M et al. (2006) Insulin-like growth factor-I increases bone sialoprotein (BSP) expression through fibroblast growth factor-2 response element and homeodomain protein-binding site in the proximal promoter of the BSP gene. *J Cell Physiol* 208, 326-335.
37. Ogata Y, Niisato N, Furuyama S, Cheifetz S, Kim RH, Sugiya H et al. (1997) Transforming growth factor- β 1 regulation of bone sialoprotein gene transcription: identification of a TGF- β activation element in the rat BSP gene promoter. *J Cell Biochem* 65, 501-512.
38. Yamauchi M, Ogata Y, Kim RH, Li JJ, Freedman LP, Sodek J (1996) AP-1 regulation of the rat bone sialoprotein gene transcription is mediated through a TPA response element within a glucocorticoid response unit in the gene promoter. *Matrix Biol* 15, 119-130.
39. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K et al. (1997) Targeted disruption of *Cbfa1* results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* 89, 755-764.
40. Hurley MM, Tetradis S, Huang YF, Hock J, Kream BE, Raisz LG et al. (1999) Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. *J Bone Miner Res*

- 14, 776-783.
41. Sabbieti MG, Marchetti L, Abreu C, Montero A, Hand AR, Raisz LG et al. (1999) Prostaglandins regulate the expression of fibroblast growth factor-2 in bone. *Endocrinology* 140, 434-444.
42. Hurley MM, Abreu C, Gronowicz G, Kawaguchi H, Lorenzo J (1994) Expression and regulation of basic fibroblast growth factor mRNA levels in mouse osteoblastic MC3T3-E1 cells. *J Biol Chem* 269, 9392-9396.
43. Ducy P, Karsenty G (1995) Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. *Mol Cell Biol* 15, 1858-1869.
44. Boudreaux JM, Towler DA (1996) Synergistic induction of osteocalcin gene expression: identification of a bipartite element conferring fibroblast growth factor 2 and cyclic AMP responsiveness in the rat osteocalcin promoter. *J Biol Chem* 271, 7508-7515.
45. Dong Z, Xu RH, Kim J, Zhan SN, Ma WY, Colburn NH et al. (1996) AP-1/jun is required for early *Xenopus* development and mediates mesoderm induction by fibroblast growth factor but not by activin. *J Biol Chem* 271, 9942-9946.
46. Aho S, Rouda S, Kennedy SH, Qin H, Tan EML (1997) Regulation of human interstitial collagenase (matrix metalloproteinase-1) promoter activity by fibroblast growth factor. *Eur J Biochem* 247, 503-510.
47. Harris SE, Guo D, Harris MA, Krishnaswamy A, Lichtler A (2003) Transcriptional regulation of BMP-2 activated genes in osteoblasts using gene expression microarray analysis: role of *Dlx2* and *Dlx5* transcription factors. *Front Biosci* 8, s1249-1265.
48. Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR, Kyung HM et al. (2003) BMP-2-induced *Runx2* expression is mediated by *Dlx5*, and TGF- β 1 opposes the BMP-2-induced osteoblast differentiation by suppression of *Dlx5* expression. *J Biol Chem* 278, 34387-34394.
49. Newberry EP, Latifi T, Towler DA (1998) Reciprocal regulation of osteocalcin transcription by the homeodomain proteins *Msx2* and *Dlx5*. *Biochemistry* 37, 16360-16368.
50. Heldin CH, Miyazono K, ten Dijke P (1997) TGF- β signaling from cell membrane to nucleus through SMAD proteins. *Nature* 390, 465-471.
51. Hall MC, Young DA, Waters JG, Rowan AD, Chantry A, Edwards DR et al. (2003) The comparative role of activator protein 1 and Smad factors in the regulation of *Timp-1* and *MMP-1* gene expression by transforming growth factor- β 1. *J Biol Chem* 278, 10304-10313.
52. Laoide BM, Foulkes NS, Schlotter F, Sassone-Corsi P (1993) The functional versatility of CREM is determined by its modular structure. *EMBO J* 12, 1179-1191.
53. Dwarki VJ, Montminy M, Verma IM (1990) Both the basic region and the 'leucine zipper' domain of the cyclic AMP response element binding (CREB) protein are essential for transcriptional activation. *EMBO J* 9, 225-232.
54. Desdouets C, Matesic G, Molina CA, Foulkes NS, Sassone-Corsi P, Brechot C et al. (1995) Cell cycle regulation of cyclin A gene expression by the cyclic AMP-responsive transcription factors CREB and CREM. *Mol Cell Biol* 15, 3301-3309.